Test Update: Pan-TRK IHC Testing for Vitrakvi®

Pranil K. Chandra, DO, *Chief Medical Officer and Vice President, Genomic and Clinical Pathology Services*
Derek Welch, MD, *Chief Medical Officer and Vice President, Anatomic Pathology Services*

March 13, 2019

Effective 3/4/2019

In late 2018, the FDA approved Vitrakvi® (larotrectinib) for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity and have no satisfactory alternative treatments or that have progressed following treatment.

PathGroup is pleased to announce the availability of Pan-TRK IHC (EPR17341) for this new indication. **Orders within the SmartGenomics family of profiles will have TRK added based on the clinical context of the patient.** The antibody is also available as a stand-alone immunohistochemistry test.

Specimen Requirements:
Pan-TRK IHC - FFPE block **OR** 1 H&E and 2 unstained slides of abnormal tissue

Sensitivity of EPR17341 to detect TRK fusions has been reported as greater than >95%.[1]

Additional information (including the molecular markers of interest and other PathGroup testing offerings) are available by contacting Oncology Customer Support at OncologySupport@pathgroup.com or 1-855-854-6473. You can also visit our website at www.pathgroup.com.

1. Hechtman JF, Benayed R, Hyman DM, et al. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. *Am J Surg Pathol.* 2017;41(11):1547-1551.